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Abstract 
Due to the emergence of widespread antibiotic resistance in bacterial pathogens, a 
greater understanding of bacterial responses to current drugs is required. A recent 
study reports that aerobic respiration is required for correct function of bactericidal 
antibiotics. Intriguingly, human macrophages and neutrophils produce the respiratory 
inhibitor nitric oxide in response to bacterial infection, so it would seem that the host 
immune system is impairing the ability of antibiotics to work effectively. To test this 
hypothesis, Escherichia coli strains were exposed to GSNO, a nitric oxide donor,  
and were subsequently exposed to antibiotics. Increasing the concentration of NO 
resulted in a dose-dependent attenuation in antibiotic efficacy, which is consistent 
with our hypothesis. Previous work in the Shepherd lab has reported the respiratory 
oxidase cytochrome bd-I as being resistant to NO, so we hypothesised that 
expression of this respiratory complex would sensitise E. coli to antibiotics when 
grown in the presence of NO. Experiments with cytochrome bd-I knockout strains 
and a NO donor were performed to test this hypothesis. This work highlights 
discrepancies between minimal lethal concentrations in the presence and absence of 
NO, which has obvious implications for our understanding of antibiotic efficacy 
during infection. 
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Chapter I 
Introduction 
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A rampant increase in antimicrobial resistance is one of the largest threats to global 
health. High resistance rates have been documented in both health-care and 
community-acquired infections around the world (World Health Organization, 
2014), spurring a need for a greater understanding of antimicrobial resistance. 
Antimicrobial agents consist of compounds which are antibacterial, antifungal, 
antiparasitic, and antiviral. This work focuses on antibacterial compounds, which are 
comprised of antibiotics and synthetic antibacterial agents. 
 
Antibiotics are natural chemical compounds produced by microorganisms to increase 
their chances of fitness over other microorganisms. These compounds can inhibit the 
growth of, or promote the death of, another microorganism. Antibiotic producers 
protect themselves from the compounds they generate by developing resistance 
mechanisms. Resistance is an evolutionary defence mechanism (or a combination of 
mechanisms) which allows a microorganism to grow in the presence of an 
antimicrobial (El-Baky 2016). Strategies a microbe may use include: inactivation of 
the antibiotic, altering an antiELRWLF¶V WDUJHW UHGXFLQJ WKHSHUPHDELOLW\RI LWVFHOO WR
reduce uptake, pumping out the antibiotic via efflux mechanisms, or changing its 
biochemical pathway (Muntia and Arias 2016). 
 
Phylogenetic reconstruction studies suggest that antibiotic resistance genes occurred 
in nature before the antibiotic era of the last 80 years, indicating that humans have 
been exposed to antibiotics for centuries (Aminov 2010). Although resistance is a 
natural process, incorrect use of antimicrobial treatment in humans and animals is 
concomitant to the acceleration of resistance rates worldwide (Dodds 2017). 
 
1.1. Emergence of antibiotic resistance 
Methicillin-Resistant Staphylococcus aureus (MRSA) is one of the most recognized 
examples of antibiotic resistance, as it is resistant to most ɴ-lactams as well as 
antimicrobials from other classes. MRSA infections are common in hospitals but 
have also become prevalent in community-acquired infections as well as livestock. 
(Arede et al. 2012). S. aureus was the first organism in which multiple drug 
resistance became published (Jevons 1961), but unfortunately this occurrence is on 
the rise with several other pathogens. As mentioned previously, antibiotic resistance 
3 | P a g e  
is an evolutionary mechanism in which bacteria that co-reside with antibiotic- 
producing microorganisms developed for survival. This form of resistance became 
associated with intrinsic resistance, whereas the current trends seen in antimicrobial 
resistance are due to acquired resistance-defined as the acquisition of resistance to an 
antimicrobial by an organism which was previously sensitive to the drug (Munita 
and Arias 2016). A microorganism is considered resistant to an antimicrobial if its 
minimum inhibitory concentration (MIC) is higher than the breakpoint value, which 
is determined by a standard test and often set by a committee, such as the European 
Committee on Antimicrobial Susceptibility Testing (Mouton et al. 2011). A 
PLFURRUJDQLVPV¶ 0,& LV GHWHUPLQHG WKURXJK in vitro testing in the clinical 
laboratory, and represents the lowest concentration of an antimicrobial that inhibits 
visible growth of the organism. The minimum bactericidal concentration (MBC) is 
determined as the lowest concentration of antimicrobial which promotes cell death 
based on the inability to re-culture a previously antibiotic-treated subculture 
(Andrews 2001). 
 
Antibiotic use as a therapy for non-bacterial infections or prophylaxis in animal 
husbandry are examples of antibiotic misappropriation which lead to an increase in 
antibiotic resistance through selective pressure. Selective pressure occurs because 
bacteria are exposed to sub-inhibitory antimicrobial concentrations which allow the 
organisms to continue growing and select for resistance or genetic and phenotypic 
variability (Andersson and Hughes 2014). Due to this selective pressure, bacteria 
could develop genetic mutations and then transfer them to other bacteria through 
horizontal gene transfer, further exacerbating the problem. 
 
Clostridium difficile is an example of an antimicrobial-resistant bacterial pathogen in 
which animal antibiotic treatment is a contributing factor to the spread of resistant 
isolates, as some human and animal isolates are closely related and interspecies 
transmission can occur through food. C. difficile resistance to tetracycline, 
doxycycline, and erythromycin antimicrobials has been reported in isolates collected 
from animals (Zidaric et al. 2012) while Tenover, Tickler, and Persing (2012) 
reported that resistance to clindamycin and moxifloxacin antimicrobials is 
widespread in human isolates from North America. Multidrug resistant (MDR) C. 
difficile isolates resistant to clindamycin, moxifloxacin, rifampin were also present in 
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isolates that they screened. C. difficile has been identified by the Centers for Disease 
Control and Prevention as one of the most urgent threats of antibiotic resistant 
microorganisms in the United States and was reported as the leading cause of death 
associated with gastroenteritis as well as one of the most prevalent health-care 
associated infections (Lessa et al. 2015). 
 
Another striking example of resistance emerging in bacterial pathogens is 
Escherichia coli ST131, a globally disseminated sequence type that is commonly 
resistant to several classes of antibiotic (Croxall et al. 2011, Totsika et al. 2011). 
This MDR strain is observed in healthcare- and community-acquired urinary tract 
infections and produces a CTX-M-15 extended spectrum ɴ-lactamase (ESBL), 
protecting the strain from the effects of ɴ-lactam antimicrobials (Petty et al. 2014). 
E. coli EC958, a WT ST131 strain is used in this study. 
 
 
1.2. Classes of antibacterial agents and modes of action 
Antibacterial agents can be classified using several methods. They are typically 
grouped by chemical structure, overall phenotypic effect, or mode of action. Table 
1.1 lists the main classes of antibacterial agents, grouped into classes based on 
FKHPLFDOVWUXFWXUHDQGEULHIO\ LGHQWLILHVHDFKFODVVHV¶EDFWHULDO WDUJHWDQGPRGHRI
action. Figure 1.1 depLFWVHDFKFODVV¶PDLQWDUJHWLQWKHEDFWHULDOFHOO(DFKFODVVLV
further described in the subsections following. 
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Antimicrobial Class Main Target Mode of Action 
Aminoglycosides 30S ribosomal subunit Inhibits protein synthesis 
Amphenicols 50S ribosomal subunit Inhibits protein synthesis 





Inhibits DNA synthesis 
Macrolides 50S ribosomal subunit Inhibits protein synthesis 
Nitrofurans Several Unknown 
Polymixins Cell membrane Disrupts membrane 
Sulfonamides Folic acid pathway Binds DHPS 
Tetracyclines 30S ribosomal subunit Inhibits protein synthesis 
 








Figure 1.1. The main targets in a bacterial cell for major classes of antimicrobials. 
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1.2.1. Aminoglycosides 
Aminoglycosides are a group of broad-spectrum bactericidal antibiotics containing 
amino sugars that are bonded by glycosidic linkage. Aminoglycosides were 
discovered when streptomycin was isolated from Streptomyces griseus in the 1940s 
(Doi Wachino, and Arakawa 2016). Over the next three decades, other antibiotics in 
this group were discovered and, subsequently, second-generation semi-synthetic 
versions were created. Common examples of aminoglycosides include kanamycins, 
neomycins, and gentamicins (Becker and Cooper 2013), of which gentamycin is  
used in this study. Streptomycin was immensely instrumental in treating tuberculosis 
following its initial discovery, and other antibiotics in this class were often used to 
treat gram-negative and some gram-positive species. They have been replaced in 
clinical practice in favour of other therapies, but are often still used to treat severe 
gram-negative bacterial infections (Galimand, Courvalin, and Lambert 2003). 
 
Aminoglycosides act by binding selectively to 16S rRNA, part of the 30s subunit, 
and interrupting protein synthesis which leads to cell death (Udumula et al. 2012). 
Upon binding to 16S rRNA, aminoglycosides cause translational errors which inhibit 
translocation. Bacteria have developed resistance to this class by methylation or 
substitution of the bases which bind these agents with 16S rRNA, reducing uptake of 
the drug through changes to membrane permeability and efflux, and most commonly 




Amphenicols are class of synthetic antimicrobials which contain a phenylpropanoid 
structure. Chloramphenicol is the most common drug from this class. It was first 
isolated as an antibiotic from Streptomyces venezuelae in the late 1940s and has 
since been chemically synthesized along with its derivatives. It is active against 
gram-positive and gram-negative bacteria and can be useful in treating bacterial 
meningitis, although it is not commonly used due to toxic side effects (Aminov 
2017). 
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Chloramphenicol is a bacteriostatic antibiotic that inhibits protein synthesis (Allsion 
et al. 1962). It irreversibly binds to the 50S ribosomal subunit and prevents chain 
elongation by inhibiting peptidyltransferase (Xaplanteri et al. 2003). Bacterial 
resistance to chloramphenicol is widely spread, with the most common resistance 




ȕ-lactam antimicrobials are a large class of bacterial agents which contain a ɴ-lactam 
ring as their core structure. There are several subclasses which include penicillins, 
cephalosporins, carbapenems, and monobactams (Aminov 2017). Penicillin was the 
first antibiotic of this class to be discovered. It is naturally produced by the 
Penicillium sp. and was discovered in the 1920s, followed by the discovery of 
cephalosporins in the 1940s from a culture of Cephalosporium fungus (Kardos and 
Demain 2011). Semisynthetic versions of penicillin were later produced to overcome 
resistance to penicillinase (methicillin) and to provide a broader-spectrum activity 
(ampicillin) (Aminov 2017). Third- and subsequent generations of ɴ-lactam 
antibiotics have since been developed, of which amoxicillin is used in this study 
(Handsfield et al. 1973). 
 
ȕ-lactam antibiotics target bacterial cell walls. They inhibit cell wall synthesis using 
several mechanisms. Penicillins prevent the cross-linking of peptidoglycan by 
binding to the active site of transpeptidase enzymes. Transpeptidases catalyse the last 
step of crosslinking the peptide chains in the cell wall. As a result of this binding, 
transpeptidases are unable to catalyse the crosslinking, weakening and eventually 
degrading the cell wall. Without a cell well, the bacterial cells lyse and cell death 
occurs (Yocum, Rasmussen, and Strominger 1980). Resistance to penicillins is 
provided by the blaZ and mecA genes which cRGH IRU ȕ-lactamase and penicillin- 
ELQGLQJSURWHLQDȕ-ODFWDPDVHVGHVWUR\ȕ-lactam rings in penicillins, rendering the 
drug ineffective. Penicillin-binding protein 2a is a specific type of transpeptidase 
ZKLFKȕ-lactam antimicrobials cannot inhibit (Blazques, et al. 2014). 
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1.2.4. Fluoroquinolones 
Fluoroquinolones are a class of broad-spectrum synthetic antimicrobials which are 
derived from a quinolone called nalidixic acid (Aminov 2017). They prevent DNA 
gyrase from supercoiling DNA in the cell. They can also interact with topoisomerase 
IV, which is needed to separate DNA, thereby inhibiting cell division. (Tran and 
Jacoby 2002). Ciprofloxacin and norfloxacin are two common examples of this drug 
class. 
 
Resistance to quinolones is encoded by the gene qnr. Quinolone resistance is 
acquired through mutations to chromosomal genes as drugs in this class are 
synthetic. These mutations have been found to be transferrable (Tran and Jacoby 
2002). Qnr can bind to DNA gyrase and diminish its ability to bind DNA in the 
gyrase-DNA complex, resulting in a decrease in available targets for quinolones 
(Tran, Jacoby, and Hooper 2005). 
 
1.2.5. Macrolides 
Macrolides are a large class of antibiotics whose basic structure is comprised of a 14- 
to 16- atom lactone ring coupled with sugar moieties. The first clinical antibacterial 
agent discovered in this group was erythromycin, which is produced by 
Saccharopolyspora erythrae (Pavlova et al. 2017), and is one of the most common 
antibiotics of this class. Other common macrolide antibiotics include azithromycin 
(Retsema et al. 1987) and clarithromycin (Morimoto et al. 1987), which are 
chemically modified second-generation drugs with improved spectrum and potency 
over erythromycin. 
 
Marcrolides inhibit protein synthesis by binding to the nascent peptide exit of 23S 
rRNA of the large subunit on the bacterial ribosome. By binding here, they can block 
the translocation reaction which results in a failure of continued growth of peptide 
chains of certain proteins (Sothiselvam et al. 2016). The most common form of 
resistance to macrolides occurs when demethylation of the 23S rRNA at the adenine 
residue A2058 does not allow the antimicrobial to bind at its target site (Aminov 
2017). 
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1.2.6. Nitrofurans 
Nitrofurans are a group of synthetic drugs recognized for their antimicrobial 
properties in the 1940s. The exact mode of action of Nitrofurans is still unknown,  
but some studies have provided general targets of nitofuran activity. Reduced forms 
of these drugs bind to ribosomal proteins by forming highly reactive intermediates 
and inhibiting protein synthesis (McCalla, Reuvers, and Kaiser 1970; McOsker and 
Fitzpatrick 1994). It has also been demonstrated that nitrofurans cause single strand 
beaks in DNA (McCalla, Reuvers, and Kaiser 1971). 
 
The most common antimicrobial in this class is Nitrofurantoin, which is used in this 
study. Nitrofurantoin is used to treat uropathogens, as there is a low incidence of 
resistance to the drug while many uropathogens are often resistant to many of the 
other antimicrobial classes (Lindgren et al. 2015). 
 
1.2.7. Polymyxins 
Polymyxins are a class of polypetide antimicrobials which generally have a cyclic 
peptide and a hydrophobic tail. They were discovered in the 1940s and are produced 
by Bacillus polymyxa. They target the cell membranes of gram-negative bacteria, 
acting as detergents to disrupt the membrane and increase membrane permeability. 
The increase in permeability results in a leakage of ions and macromolecules 
necessary for the cell to survive (Sahala and Dixon 2008; Sader et al. 2015). A 
secondary mode of action has been suggested that polymyxins also inhibit type II 
NADH-quinone oxioreducatases (Deris et al. 2016). 
 
Polymyxin B and polymyxin E (also known as colistin) are the most commonly used 
antimicrobials in this class. They are usually reserved as a last resort drug, but can be 
used for the treatment of MDR Enterobacteriacea, Acinetobacter baumannii, and 
Psuedomonas aeruginosa (Tran et al. 2016). An increase in MDR strains requiring 
colistin treatment have resulted in an emergence of colisitn resistance. It has been 
suggested that a possible mechanism for colistin resistance is the addition of 
phospohoethanolamine to lipid A in the outer membrane (Qureshi et al. 2015). 
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1.2.8. Sulfonamides 
Sulfonamides are a class of synthetic antimicrobials which are derivatives of 
sulphanilamide, an analog of p-aminobenzoic acid. They target the enzyme 
dihydropteroate synthase (DHPS), which catalzyes a reaction that forms 
dihydropteroic acid. The formation of dihydropteroic acid is necessary for bacteria to 
synthesize folic acid. Targeting DHPS blocks folic acid synthesis in bacteria, which 
bacterial organisms need for survival (Skold 2000). 
 
Sulfonamides were once a popular class used in antimicrobial treatment, therefore 
resistance is these drugs is common for many pathogens. Resistance is linked to 
mobile genetic elements, making it difficult to eliminate as integrons promote the 
rapid spread of antimicrobial resistance genes (Aminov 2017). 
 
1.2.9. Tetracyclines 
Tetracyclines are a class of broad-spectrum antibiotics discovered in the 1940s. The 
first antibiotic discovered was chlortetracycline, which is produced by Streptomyces 
aureofacines (Aminov 2017). They inhibit protein synthesis by preventing tRNA 
from accessing the acceptor site in the ribosome (Chopra and Roberts 2001). 
 
Wide-spread resistance to tetracycline exists because of extensive use of sub- 
therapeutic levels of these antibiotics in animal feed to promote animal growth. 
Tetarycline resistance commonly occurs via gene acquisition. Some of these genes 
code for efflux pumps, while others code for protein protecting ribosomes (Chopra 
and Roberts 2001). The tet(X) gene has also been shown to provide resistance as it 
encodes for an enzyme deactivating tetracycline molecules. To combat resistance 
issues, second- and third-generation tetracyclines were developed for clinical use. 
Third-generation tigecycline has shown to have a small level of resistance in clinical 
isolates and is an effective treatment for many MDR pathogens (Aminov 2017). 
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1.3 Distinguishing between bacteriostatic and bactericidal antimicrobials  
Antibiotics can also be grouped into two categories based on their overall phenotypic 
effect on the microorganism; growth is inhibited by bacteriostatic antibiotics while 
bactericidal antibiotics elicit cell death. However, it has been argued in literature that 
the distinction of the in vitro definitions of bacteriostatic and bactericidal antibiotics 
are not clinically relevant, especially when treating gram-positive bacterial infections 
(Pankey and Sabath 2004), abdominal infections, skin infections, soft tissue 
infections, and pneumonia (Nemeth, Oesch, and Kuster 2015). One the other hand, 
Findberg et al. (2004) concluded that antimicrobials with in vitro bactericidal 
activity are needed to treat endocarditis and meningitis, even though bactericidal 
agents can have disadvantages such as inflammation from cytokines as a result of 
bacterial products from lysed cells. There is also the argument that bactericidal 
treatment is superior to bacteriostatic treatment simply because eradication of 
bacteria diminishes the likelihood of resistance development (Stratton 2003). 
 
Despite clinical studies showing the distinction between bacteriostatic and 
bactericidal antimicrobials to be irrelevant, microbiological and molecular studies 
have demonstrated that these two categories have very different phenotypic effects. 
Levin et al. (2017) hypothesized that a reduction in growth due to bacteriostatic 
antibiotic treatment is a result of a reduced ribosome count in these cells, since the 
majority of bacteriostatic antibiotics mainly target translation machinery. They 
postulated their query on other studies which demonstrated that numbers of 
ribosomes in a cell are proportional to the growth rate of the bacteria, and their 
results supported their hypothesis. Belenky et al. (2015) demonstrated that treatment 
with different classes of bactericidal antibiotics produced similar metabolic changes 
which are indicative of toxic metabolic by-products building up. 
 
1.4. The impact of bacterial respiration upon antibiotic resistance 
A recent study has reported that bacterial respiration exacerbates the toxic effects of 
bactericidal antibiotics, and the presence of bacteriostatic agents were shown to 
abrogate this potentiation. In this study, bacteriostatic drugs suppressed respiration, 
which in turn affected bactericidal antibiotic lethality (Lobritz et al. 2015).  
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The inhibition of the respiratory chain affects antibiotic lethality in several ways. By 
inhibiting respiratory processes, the cell is unable to grow, which can be protective 
for bacteria that are being treated with antibiotics which target growth activities 
(Baek, Li, and Sasseti 2011), such as ȕ-lactams targeting cell wall synthesis. 
Inhibition of respiration can also attenuate the effectiveness of aminoglycosides 
which require a threshold of PMF for the organism to uptake the drug. If respiration 
is inhibited, antibiotic uptake is arrested and ultimately diminishes antibiotic 
effectiveness (Allison, Brynildsen, and Collins 2011). Another means in which 
inhibition affects antibiotic lethality is that by impeding bacterial metabolism, the 
toxic metabolic by-products produced during antibiotic treatment are reduced 
(Belenky et al. 2015; Dwyer et al. 2014). This has implications for the role of the 
respiratory inhibitor nitric oxide during infection, which is introduced in Section 
1.6 following a brief introduction to bacterial respiration in Section 1.5 below. 
13 | P a g e  
1.5. The aerobic respiratory chain of E. coli 
 
During bacterial respiration, an energized state is produced by reactions resulting in 
electron transport. During electron transport, there is a charge separation of protons 
from hydroxyl ions occurring across the surface of the cytoplasmic membrane, 
creating an electrochemical potential and pH difference across the membrane. This 
potential energy state is known as the proton motive force (PMF) (Krulwich, Sachs, 
and Padan 2011). The energized state in the proton motive force can be conserved in 
the form of ATP or used for other purposes in the cell. The PMF is produced by 
reactions from the enzymes, proteins, and non-protein molecules of the electron 
transport chain (ETC) (Price and Driessen 2010). 
 
The role of the ETC is to facilitate electron transfer from electron donor to acceptor 
and to initiate the process of energy conservation. The ETC is branched so that it can 
be adaptable under varying conditions in the environment (Steinsiek, Stage, and 
Bettenbrock 2014). Several enzymes are involved in the oxidation and reduction 
process of electron transport which include dehydrogenases, flavoproteins, iron-
sulfur proteins, and cytochromes. In the ETC, electrons are transported between 
donors and acceptors, of which oxygen is a final electron acceptor during aerobic 
respiration (Henkel et al. 2014). 
 
Electron carriers are arranged throughout the cytoplasmic membrane with 
dehyrogenases being the first stop in the chain, and during aerobic respiration the 
terminal oxidases are the last carriers involved. As the final electron carriers in the 
aerobic ETC, terminal oxidases donate electrons and protons to the terminal electron 












Figure 1.2. Generalized electron transport chain of E. coli. The ETC transfers 
electrons from donors to acceptors and participates in energy conservation. 
Dehydrogenases catalyse the removal of H+ from metabolites and transfer electrons 
to the quinone pool in the cytoplasmic membrane. Quinones shuttle electrons from 
dehydrogenases to terminal oxidases, where the final electron acceptor is reduced. 
E. coli¶VWHUPLQDOR[LGDVHs also generate a PMF and Cytochrome bo' acts as a proton 
pump, while Cytochrome bd does not. In the figure above, O2 is shown as the final 
electron acceptor, which is reduced to water.   
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1.5.1 The terminal oxidases of the E. coli respiratory chain 
E. coli¶V DHURELF UHVSLUDWRU\ FKDLQ FRQWDLQV WZR WHUPLQDO TXLQRO R[LGDVHV- 
cytochrome bo' and cytochrome bd. Because E. coli is a facultative anaerobe, it can 
grow under different conditions of oxygen availability, where different oxidases are 
expressed: cytochrome bo' is a low affinity oxidase and is expressed under aerobic 
conditions, and cytochrome bd is a high affinity oxidase and is expressed under 
PLFURDHURELF FRQGLWLRQV '¶0HOOR+LOO DQG3RROH E. coli terminal oxidases 
contain heme prosthetic groups which lose or gain a single electron in the process of 
oxidation or reduction. The terminal oxidases of E. coli differ in their reduction 
potential and are designated according to the types of hemes they contain (Puustinen 
and Wikstrom 1991). Cytochrome bo' is composed of the protein cluster CyoABCD; 
cytochrome bd-I is composed of CydABX. In addition, cytochrome bd-I is tolerant 
to the respiratory inhibitor nitric oxide (Mason et al, 2009; Shepherd et al. 2016), 
which is encountered during infection, which has implications for the efficacy of 
antibiotics (introduced in Sections 1.5 and 1.6). 
 
Bacterial terminal oxidases could potentially be promising new drug targets. 
Previously, the contribution that terminal oxidases make towards bacterial fitness 
have been described for S. aureus (Hammer et al. 2013). Also, Kalia et al. (2017) 
found that inhibition of the two terminal oxidases of Mycobacterium tuberculosis 
allowed a bacteriostatic drug to perform in a bactericidal manner. It has also been 
shown that the virulence of some pathogenic bacteria is dependent on cytochrome bd 
(Giuffre et al. 2014). Previous work in the Shepherd lab confirmed that cytochrome 
bd-I is resistant to NO (Mason et al. 2009), allowing bacteria to survive nitrosative 
stress produced by its human host. Figure 1.3. demonstrates the effect of NO in E. 
coli¶V UHVSLUDWRU\ FKDLQ 8QGHUVWDQGLQJ WKH UROH RI WHUminal oxidase expression in 
antibiotic resistance would further propel research towards new strategies for 
combatting this worldwide problem. 












Figure 1.3. The effect of NO in E. coli¶VUHVSLUDWRU\FKDLQ Cytochrome bo' 
(CyoABCD protein cluster) is the dominant oxidase expressed in high oxygen 
conditions and its activity is inhibited by NO. Cytochrome bd-I (CydABX protein 
cluster) is primarily expressed under low oxygen conditions and is tolerant to NO, 
allowing respiration to continue in the presence of NO.
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1.6. E. coli encounters the respiratory inhibitor nitric oxide (NO) during 
infection 
The human body has its own defence mechanisms against bacteria. During infection 
NO is produced endogenously by mammalian innate immune cells, mostly 
macrophages and neutrophils. NO is a small molecule which damages 
microorganisms through nitrosative damage to a wide range of cellular targets, 
including thiols and metal centres of bacterial proteins. A vast range of organisms 
are effectively targeted by NO, including pathogenic strains of E. coli. NO is 
bactericidal at high concentrations, but elicits bacteriostatic effects via inhibition of 
the terminal oxidases of the respiratory chain (via binding to haem cofactors) (Fang 
1997; Giuffre et al. 2014). 
 
1.7. Hypothesis: NO can undermine the efficacy of antibiotics 
Since terminal oxidase activity has been shown to have a positive effect upon the 
potency of bactericidal antibiotics (Lobritz et al. 2015), the terminal oxidase 
inhibitor NO is anticipated to diminish the toxic effects of these antimicrobials. This 
study aims to demonstrate that NO impairs the efficacy of bactericidal antibiotics via 
the use of GSNO, a nitric oxide releaser. Furthermore, the expression of NO-tolerant 
(cytochrome bd-I) and NO susceptible (cytochrome bo') terminal oxidases is also 
anticipated to impact upon the potency of antibiotics. 
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Chapter 2 
Materials and Methods 
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2.1. Bacterial Strains 
Table 2.1. E. coli strains used in this work. 
 
Strain # Strain Description Source/Reference 
MS2 K-12 MG1655 WT Bachmann, 1996 
MS10 ST131 EC958 WT Totsika et al., 2011 
MS15 MG1655 cydAB::Cm Shepherd Laboratory 
MS52 K-12 BW25113 WT Datsenko and Wanner, 
2000 
MS493 BW25113 cyoA::Kan Baba et al., 2006 
MS404 MG1655 cydAB::Cm (pSU2718-cydABX) Shepherd Laboratory 
 
2.2. Chemicals and water 
 
2.2.1. Purchased chemicals 
 
All chemicals were purchased from Sigma Aldrich unless otherwise stated. Agar, 
tryptone, and yeast extract were purchased from Oxoid. NaCl was purchased from 
Fisher Scientific. 
2.2.2. GSNO preparation 
 
GSNO was prepared by dissolving 3.08g reduced glutathione and 0.69g NaNO2 into 
18 ml water. 862 µl of 36% HCl was then added (11.65M) to the solution which was 
covered with foil and stirred on ice for 40 minutes. 20 ml of acetone was added to 
the solution which stirred for another 10 minutes. The precipitate was collected by 
vacuum filtration while washed with five 2 ml volumes of cold water, three 10 ml 
volumes of acetone, and three 10 ml volumes of diethyl ether. The precipitate was 
dried overnight in a vacuum desiccator lined with CaCl2. The pink powder 
precipitate was stored at -80ºC for up to one month. 
GSNO concentration was determined by dissolving the powder described above into 
water and measuring the absorbance at 545 nm. The equation below was used to 
calculate the concentration. ܣ545 = ࢉ࢕࢔ࢉࢋ࢔࢚࢘ࢇ࢚࢏࢕࢔  × ࢒ࢋ࢔ࢍ࢚ࢎ × ࢿ 
 
İ 15.9 M-1 cm-1 at 545 nm (Mohr et al. 1999), length = 1 cm. 
 
GSNO was filter sterilised using 0.22 µm Millipore filters before measuring the 
absorbance. 
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2.2.3. Water and sterilization 
 
Distilled-deionised water was used unless otherwise stated. Milli-Q water was when 
greater sterility was needed. Growth media was sterilized by autoclaving at 121ºC, 
15 psi for 20 minutes. 
2.3. Media 
 
2.3.1. LB medium 
 
LB broth was made by dissolving 10g NaCl, 10g tryptone, and 5g yeast extract into 
distilled-deionised water to make up a 1L solution. To make LB agar, 15g of dried 
nutrient agar was added to the solution. 
2.3.2. M9 minimal medium 
 
M9 medium was made by dissolving 200 ml 5X M9 salts, 2 ml 1M MgSO4, 100 µl 
1M CaCl2, 20 ml 20% Glucose, and 10 ml 10% (w/v) casamino acids in water to 
make up to a 1L solution. 5X M9 salts contained 80.24g Na2HPO4.2H2O, 15 g 
KH2PO4, 2.5 g NACl, and 5 g NH4Cl dissolved in water to make up a 1L solution. 
Casamino acids 10% (w/v) were prepared by adding dried casamino acids to water to 
make up a 100 ml solution, autoclaved and cooled before use. 
2.4. Antibiotics 
 
Amoxicillin (AMX) stock solutions were prepared at 1 mg/ml dissolved in DMSO. 
Gentamycin (GM) stock solutions were prepared at 1 mg/ml dissolved in water. 
Stocks of AMX and GM were stored at -20ºC. Nitrofurantoin (NF) was prepared 
fresh for daily use at 10 mg/ml. It was dissolved in DMSO and serially diluted in M9 
media to working concentrations. 
2.5. Antibiotic Concentrations 
 
E. coli cells were treated with AMX at 40 µg/ml, (5x) minimum inhibitory 
concentration (MIC), GM between 10 µg/ml-100 µg/ml, (5x)-(50x) MIC, and NF at 
100 µg/ml (MIC value is 64 µg/ml which is bacteriostatic, so we treated with a 
higher dose). MIC values were based on the BSAC MIC and zone diameter 
breakpoint tables for Enterobacteriacae (BSAC 2013). 
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2.6. Growth Conditions 
 
E. coli overnight cultures were grown at 37ºC in LB media shaking at 180 rpm in 
conical flasks. Cultures for time-kill assays were diluted from the overnight culture 
into M9 minimal medium supplemented with 0.1% casamino acids. Cells were 
grown at 37ºC shaking at 180 rpm in conical flasks. 
2.7. Time-Kill and Minimum Bactericidal Concentration Assays 
 
Overnight samples of E. coli were diluted 1:100 into 10 ml of fresh M9. Each strain 
was grown aerobically to 108 cfu/mL. Cells were aliquoted into sterile 15 mL falcon 
tubes and GSNO was added to cells in one of the falcon tubes and Milli-Q water was 
added to cells in the other falcon tube. Cells were then incubated for 30 minutes at 
37ºC. Cells were aliquoted into sterile 1.5 ml Eppendorf tubes and appropriate 
antibiotics added. At specified time points, samples were taken from each culture 
and serially diluted 100-107 into fresh M9 across a 96-well plate. Two biological 
repeats were included for every assay and at least six technical repeats. 
Viable counts were determined by spotting samples from the dilutions described 
above onto LB agar. Agar plates were inverted once the spotted samples were 
absorbed by the agar and grown overnight at 37ºC. Colonies were counted the 
following day and percent survival determined by comparing the cfu/ml at each time 
point to the initial cfu/ml. Percent survival is presented on a log10 scale in all figures. 
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Chapter 3 
Results 
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3.1. Nitric oxide impairs the efficacy of bactericidal antibiotics 
 
3.1.1 Attenuation of antibiotic efficacy is NO dose-dependent in E. coli K-12 
 
To investigate the efficacy of bactericidal antibiotics in the presence of NO, a well 
characterized E. coli K-12 strain, BW25113 WT, was exposed to a NO donor, S- 
Nitrosoglutathione (GSNO), and subsequently treated with Amoxicillin (AMX), a ɴ- 
lactam bactericidal antibiotic described in Section 1.2.3. Cultures were grown 
aerobically as described in Section 2.6 and then treated with 40 µg/mL AMX (5x 
MIC), after a 30-minute exposure to GSNO. A time-kill analysis of E. coli K-12 is 
presented in Figure 3.1 as percent survival over time, determined by comparing 
cfu/mL of samples taken at each time point to the cfu/mL at t = 0. Figure 3.1A 
tracks the GSNO dose response with AMX for E. coli BW25113 WT over 2 hours. 
Cultures were exposed to either 2mM, 5mM, 10mM or 15mM concentrations of 
GSNO before treatment with AMX. As the concentration of GSNO increased, the 
bactericidal effects of AMX decreased. Figure 3.1B shows the % survival for E. coli 
BW25113 WT at t=2h. When treated with AMX only, only 1.6 % of the cells 
survival. When exposed to 2mM GSNO, some alleviation was seen, as the survival 
rose to 2.9%. However, a pre-treatment with 15mM of GSNO provided the greatest 
protection from AMX, as the strain had a survival of 151.8% at t=2h. 
 
To determine if the same effects could be observed in other E. coli K-12 strains, 
another well-characterized strain, E. coli MG1655 WT, was also treated with AMX 
after GSNO exposure. As 15mM GSNO was most effective in relieving AMX- 
mediated killing in the BW25113 WT strain, the MG1655 WT strain was exposed to 
a 15mM GSNO concentration over four hours to asses if the same trend was 
observed at later time points. Consistent with the BW25113 WT strain data, Figure 
3.1C displays attenuation of antibiotic efficacy in E. coli MG1655 WT over 4 hours 
when treated with AMX after NO exposure. Overall, the data in Figure 3.1 A, B, 
and C demonstrated that NO impairs the efficacy of AMX in E. coli K-12. 
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Figure 3.1 E. coli K-12 strains treated with AMX +/- GSNO exposure. (A) GSNO 
dose response of E. coli BW25113 WT treated with 40 µg/mL AMX. (B) % survival 
comparison of E. coli BW25113 WT GSNO dose response at t=2h. Arrows highlight 
differences in survival between 2mM GSNO +AMX and 15mM GNSO + AMX in 
comparison with AMX only treatment. (C) % survival of E. coli MG1655 WT 
treated with 40 µg/mL AMX. Error bars represent standard deviation of six repeats, 
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3.1.2 Antibiotic efficacy is attenuated in pathogenic E. coli in the presence of 
NO 
To determine if antibiotic efficacy is also attenuated in pathogenic E. coli in the 
presence of NO, a well characterized pathogenic E. coli ST131 strain, EC958 WT, 
was treated with a bactericidal antibiotic in the presence of GSNO. Because the 
EC958 WT strain contains a CTX-M-15 type extended-VSHFWUXP ȕ-lactamase 
(ESBL) (Petty et al. 2014), it is inherently resistant to AMX. Therefore, the EC958 
WT strain was assessed with Gentamycin (GM), an aminoglycoside, described in 
Section 1.2.3. To compare the GM results with AMX, one of the K-12 strains, E. 
coli BW25113 WT, was treated with 10 µg/mL of GM (5x MIC) after 30 minutes of 
15mM GSNO exposure. Consistent with the AMX results, Figure 3.2A 
demonstrates that antibiotic efficacy is attenuated when E. coli K-12 is treated with 
GM after GSNO exposure. E. coli EC958 WT was then treated with GM after 15mM 
GSNO exposure. At 5x the MIC, no killing was exhibited over the 2-hour time 
period (data not shown). E. coli EC958 WT was then treated with higher 
concentrations of GM. Figure 3.2B displays results for treatment with 25 µg/mL 
(12.5x MIC) and 100 µg/mL (50x MIC) GM after GSNO exposure. Antibiotic 
treatment with GM was ineffective at 25 µg/mL with the cell survival over 100% at 
t=2(h). However, when E. coli EC958 WT was treated 100 µg/mL GM, cell survival 
was less than .001% at t=2(h) when treated with only the antibiotic. When pre- 
exposed to GSNO, cells treated with 100 µg/mL of GM exhibited 54% survival at 2 
hours (Figure 3.2C), demonstrating that the antibiotic efficacy was attenuated in the 
presence of NO. 
In addition to AMX resistance, E. coli EC958 WT is resistant to several classes of 
antibiotics (Croxall et al. 2011, Totsika et al. 2011). Since treating E. coli ST131  
was only successful at concentrations much higher than the MIC in the 2 hour 
experiment, the EC958 WT strain was treated with another antibiotic at a dose much 
closer to the MIC. Nitrofurantoin (NF), a Nitrofuran antibiotic described in Section 
1.4.5., was used to evaluate both the K-12 and pathogenic strains. Figure 3.3A and 
Figure 3.3B display results of the treatment of E. coli BW25113 WT (A) and E. coli 
EC958 WT (B) with 100 µg/mL NF (>1.5x MIC) with and without GSNO exposure. 
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Unexpectedly, no alleviation of NF-mediated killing was observed when either stain 















15 mM GSNO 
 
15 mM GSNO + 10 µg/mL GM 
 






























0 0.5 1 
 
15 mM GSNO 
 
15 mM GSNO + 25 µg/mL GM 
 
15 mM GSNO + 100 µg/mL GM 
 
25 µg/mL GM 
 



























































































Figure 3.2. Time kill assay of E. coli treated with Gentamycin. (A) BW25113 WT 
K-12 strain treated with 10 µg/mL Gentamycin. +/- 15mM GSNO. (B) Pathogenic 
EC958 WT ST131 strain treated with 25 µg/mL and 100 µg/mL Gentamycin +/- 
15mM GSNO. (C) % survival of EC958 WT at t=2h. Error bars represent standard 
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Figure 3.3 Time kill assays of E. coli treated with nitrofurantoin. (A) BW25113 WT 
and pathogenic ST131 strain (B) EC958 WT treated with Nitrofurantoin +/- 15mM 
GSNO. Error bars represent standard deviation of six repeats, including two 
biological repeats. 
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3.1.3 Exposure to NO increases the Minimum Bactericidal Concentration 
 
To determine whether the minimum bactericidal concentration (MBC) is enhanced 
or diminished when E. coli is in the presence of NO, E. coli K-12 and pathogenic 
strains were treated with a range of antibiotic concentrations after exposure to 15 
mM of GSNO. An increase in the MBC would result in the curve moving to the right 
and indicating that a higher dose of antibiotic would be required to effectively kill 
bacteria; a decrease in the MBC would result in the curve moving to the left and 
indicating that the addition of NO increased bacterial killing. Alternatively, if GSNO 
were to inactivate the antibiotic, it would be expected that there would be at least 
100% survival of bacteria pre-exposed to GSNO at every concentration since the 
cells would replicate within the 90-minute incubation period. Figure 3.4A shows a 
dose response with GM +/- 15 mM GSNO for E. coli BW25113 WT. Cells were 
treated with a 1000-fold range of GM from 0.1 µg/mL to 100 µg/mL with samples 
taken after 90 minutes of exposure to GM. An increase can be observed in the MBC 
curve from 1 µg/mL to 100 µg/mL. In Figure 3.4B E. coli EC958 WT also shows 
attenuation of efficacy for GM between 0.5 µg/mL to 1 mg/mL in presence of NO, 
as well as slight resistance to the antibiotic compared to the K-12 strain.  
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Figure 3.4 Dose response of E. coli (A) K-12 BW25113 WT and (B) pathogenic E. 
coli EC958 WT treated with a range of Gentamycin concentrations +/- 15mM 
GSNO. % survival is based on a 90-minute exposure to antibiotic and shown as a 
function of Gentamycin concentration. Error bars represent standard deviation of at 
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3.2 The ability of E. coli to respire in the presence of nitric oxide 
influences antibiotic efficacy 
3.2.1 Attenuation of antibiotic efficacy is not as pronounced in a cytochrome boඁ 
mutant as a WT strain 
 
Since the toxic effects of bactericidal antibiotics are dependent upon bacterial 
respiration (Lobritz et al. 2015), it was hypothesised that changes in the expression 
of cytochromes in E. coli¶VUHVSLUDWRU\FKDLQFRXOGUHOLHYHVRPHEDFWHULFLGDOHIIHFWV
of an antibiotic. Cytochrome boඁ, described in Section 1.5.1, is predominantly 
expressed in aerobic conditions. A deletion in the cyo operon is likely to make the 
cells more reliant on the NO-tolerant cytochrome bd-I, allowing E. coli to undergo 
aerobic respiration in the presence of NO and remain sensitive to NO. It was 
therefore anticipated that the ability of NO to decrease antibiotic efficacy would be 
attenuated in a cytochrome boඁ mutant. To test this hypothesis, E. coli K-12 strain 
BW25113 ȴcyoA, was treated with 40 µg/mL of AMX after a 30-minute exposure to 
15 mM GSNO. The % survival of samples taken over 2 hours is presented in Figure 
3.5. The NO-mediated decrease in antibiotic efficacy was not as dramatic in the 
ǻcyoA strain (Figure 3.5A) compared to the E. coli BW25113 WT (Figure 3.5B). 
$OVR WKH ǻcyoA strain appears to be more resistant to AMX than the WT when 
treated with the antibiotic alone, as the % survival is higher at both t=1h (Figure 
3.5C) and t=2h (Figure 3.5D) compared to the WT strain, yet the % survival is not 
KLJKHUIRUWKHǻcyoA cultures pre-exposed to GSNO than the WT strains. 
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3.2.2 When NO-tolerant cytochrome bd-I is lost, attenuation of antibiotic 
efficacy is more pronounced in the mutant strain than WT strain 
 
As described in Section 1.5.1, cytochrome bd-I is a high affinity oxidase and is 
predominantly expressed under microaerobic conditions. Studies have shown this 
respiratory cytochrome to be NO-tolerant (Mason et al. 2009). A deletion in the 
cydABX operon would diminish the ability of the cells to respire in the presence of 
NO: it was anticipated that this would increase the ability of NO to alleviate 
antibiotic toxicity. To test this hypothesis, E. coli K-12 strain E. coli MG1655 
ȴcydAB was treated with 40 µg/mL of AMX in the presence of 9.5mM GSNO. % 
survival of E. coli MG1655 ȴcydAB treated with AMX only and pre-treated with 
GSNO is shown in Figure 3.6A. E. coli MG1655 WT is shown in Figure 3.6B. 
GSNO is slightly more effective in alleviating AMX±PHGLDWHGNLOOLQJLQWKHǻcydAB 
strain in comparison to the WT strain (shown clearly at t = 1h). A strain of E. coli 
MG1655 containing a cytochrome bd-I overexpression plasmid (pSU2718-cydABX) 
was also treated with 40 µg/mL of AMX in the presence of 9.5mM GSNO. Because 
cytochrome bd-I is tolerant to NO, overexpression was predicted to reduce the ability 
of GSNO to alleviate AMX-mediated killing and AMX would be more lethal to the 
bacterium. In Figure 3.6C, the % survival of this strain in the presence of NO is 
ORZHUWKDQERWKWKHǻcydAB and WT strains, further illustrated in Figure 3.6D. 
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Figure 3.6 % survival of wild type and ǻcydAB E. coli K-12 strains in response to 
amoxicillin. (A) E. coli 0*ǻcydAB (B) E. coli MG1655 WT and (C) E. coli 
MG1655 pSU2718-cydABX, and overexpression of cytochrome bd-I (D). 
Comparison of three strains at t=1h and t=2h when treated with 40 µg/mL in the 
presence of NO. Error bars represent standard deviation of at least 5 repeats, 
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Chapter 4 
Discussion 
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4.1. Nitric oxide affects the potency of bactericidal antibiotics 
 
Lobritz et al. (2015) observed that the stunted growth effects of bacteriostatic 
antibiotics were a result of a suppression in cellular respiration, while bactericidal 
antibiotics promoted cell death by accelerating respiration. Dwyer et al. (2014) and 
Kohanski et al. (2007) also found that treatment with different classes of bactericidal 
drugs resulted in an elevation of oxygen consumption and an induced depletion of 
NADH, indicating that cellular respiration was accelerated. When Lobritz et al. 
(2015) combined the antagonistic phenotypic outcomes of bacteriostatic and 
bactericidal drugs, they discovered that treating bacteria with a bacteriostatic 
antibiotic prior to bactericidal treatment stifled the deleterious effects of the 
bactericidal antibacterial. They concluded that the state of bacterial metabolism 
significantly influences antibiotic efficacy. 
Several hypotheses indicate that inhibition of the respiratory chain thwarts the 
effectiveness of bactericidal antibiotics. Antibiotic uptake is hindered without the 
presence of the PMF which is generated during respiration (Allison, Brynildsen, and 
Collins 2011); respiration is needed for cell growth and many bactericidal antibiotics 
target cell growth processes (Baek, Li, and Sasseti 2011); inhibition of respiration 
hinders the production of toxic metabolic by-products, which are a consequence of 
downstream metabolic changes that occur when the antibiotic interacts with its main 
cellular target (Belenky et al. 2015). 
This work employs those results and hypothesizes that since NO is a respiratory 
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4.1.1. Attenuation in the presence of NO is dose dependent 
 
This study found that the attenuation of bactericidal antibiotics occurs in the 
presence of NO and that attenuation is dose dependent. E. coli K-12 was exposed to 
a range of GSNO concentrations varying from 2mM-15mM prior to bactericidal 
antibiotic treatment. When exposed to GSNO before antibiotic treatment, E. coli 
cultures had an incremental increase in % survival correlating with an increase in 
GSNO concentration (Figure 3.1A). 15mM GSNO was determined to be the most 
effective dose to use in the study (Figure 3.1B). GSNO itself has antibiotic 
properties; in small concentrations it is bacteriostatic and in larger concentrations 
bactericidal (Shairer et al. 2012). E. coli was treated with a GSNO only control to 
verify that the GSNO concentration itself was not killing the bacteria. At 15mM, 
GSNO appeared to be bacteriostatic as the % survival of the bacteria was lower than 
the % survival of the no treatment group, yet the % survival at t=1 and t=2 was not 
lower than the % survival at t=0, indicating that GSNO was stunting the growth of 
the culture at this concentration, but not killing the cells. Further studies could have 
been done with higher concentrations to determine the maximum concentration of 
GSNO before the treatment was determined to be bactericidal EXW IRU WKLV VWXG\¶V
purposes 15mM was sufficient to demonstrate that bactericidal antibiotics are 
attenuated in the presence of NO (Figures 3.1-3.2, 3.4-3.6). 
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4.1.2. Attenuation occurred in both K-12 and pathogenic strains 
Antibiotic attenuation occurred in both K-12 and pathogenic E. coli (Figures 3.1- 
3.2). The pathogenic strain, E. coli EC958 WT, appeared to be a bit resistant to GM, 
as the MBC shifts for the pathogenic strain (Figure 3.4B) in comparison with the 
WT strain (Figure 3.4A). One possible explanation could be that the pathogenic 
strain contained a subpopulation of persister cells. This could have been tested 
further by completing a second time-kill assay on colonies from overnight growth 
that were previously treated with GM (Balaban et al 2004). To further investigate 
these results, an MIC susceptibility test (Andrews 2001) could be performed on the 
EC958 WT strain to determine if the MIC is indeed higher in the pathogenic strain 
than the K-12 strain. 
 
The EC958 strain is also resistant to AMX as well as several other antibiotics in 
other classes. In another study in the Shepherd lab, the EC958 strain was shown to  
be sensitive to Nitrofurantoin, Meropenem, and Colistin in addition to GM. The 
time-kill assays were repeated using NF for bactericidal treatment of the BW25113 
WT and EC958 WT strains. Surprisingly, no attenuation of antibacterial treatment 
was observed for either strain (Figure 3.3A-B). Perhaps these unexpected results are 
due to treatment with too low of a drug concentration as NF is bacteriostatic at lower 
concentrations and bactericidal at higher concentrations. Lindgren et al. performed 
time-kill assays on clinical isolates of E. coli (2015) and found that in their isolates  
at least 8x the MIC was required for bactericidal effect. However, the MICs for the 
isolates in their study were lower than the MIC breakpoint value listed in the BSAC 
susceptibility table which was referenced for this study (BSAC 2013). Again, 
experiments to determine the MIC of NF for the BW25113 WT and EC958 strains 
could be performed. 
 
4.1.3. A large discrepancy occurs in the Minimum Lethal Concentration for E. 
coli in the presence of NO 
In Figure 3.4 we observed that exposure to NO increases the MBC for both the E. 
coli K-12 and pathogenic strain when treated with GM. These results further support 
the observation that NO attenuates antibiotic efficacy, as bacterial killing is still 
present after bactericidal treatment, but at much higher concentrations. This provides 
evidence that GSNO is not inactivating the drug but rather has a diminishing effect 
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on the capabilities on the antibiotic. If GSNO were inactivating the drug, we would 
expect to see a % survival > 100% at each concentration, as the cells would replicate 
over a 90-minute incubation period. This would result in more of a straight line, 
rather than a curve since an increase in antibiotic concentration would not result in a 
decrease in % survival. In the BW25113 WT (Figure 3.4A) and the EC958 WT 
(Figure 3.5B) pre-exposure to GSNO resulted in a decrease in survival rates when 
treated with GM and is represented visually by a curved graph, demonstrating that an 
increase in concentration resulted in a decrease in survival. While the EC958 WT 
(Figure 3.5B) MBC is less pronounced in the presence of GSNO in comparison to 
the BW25113 WT (Figure 3.5A), a downward trend can be observed around 100 
µg/mL. Further studies could be done to explore this by incubating each antibiotic 
with GSNO overnight and comparing the percent survival of E. coli treated with the 
GSNO/antibiotic mixture and E. coli treated with the antibiotic alone, as the 
concentration of NO would diminish over a longer period of time. 
 
4.2 Cytochrome expression also impacts the potency of bactericidal antibiotics 
Based on the results that AMX and GM were attenuated in the presence of NO, we 
wanted to examine if the expression of NO-tolerant cytochrome bd-I would curtail 
these effects. An E. coli BW25113 ȴcyoA strain was treated with 40 µg/ml AMX 
after exposure to 15mM GSNO. It was expected that the deletion of the cyo operon 
would result in a higher level of dependence on cytochrome bd-I. Since this terminal 
oxidase is tolerant to NO, deletion of the cyo operon would allow E. coli to respire in 
the presence of NO. As demonstrated in Lobritz et al. (2015), bactericidal activity 
correlated with accelerated respiration, therefore E. coli¶VDELOLW\WRUHVSLUHLQWKH
SUHVHQFHRI12ZRXOGGLPLQLVK12¶VDELOLW\WRDWWHQXDWH$0;¶VOethality. 
 
The results in Figure 3.5 are surprising because we expected that dependence on the 
NO tolerant cytochrome bd-I would allow E. coli to respire in the presence of NO. 
Consequently, it was expected that no attenuation of AMX would occur, as the 
bactericidal nature of the antibiotic would increase respiration, resulting in toxic 
effects for E. coli. We expected that the survival rate would be close to, if not equal 
to, that of AMX treatment alone. Treatment with AMX in the presence of NO did  
not alleviate AMX-mediated killing as dramatically as was observed with E. coli 
BW25113 WT. 
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We also hypothesized that a loss of cytochrome bd-I function would result in a 
greater attenuation of antibiotic efficacy than a WT strain. We tested this hypothesis 
by treating an E. coli MG1655 ȴcydAB mutant with AMX after GSNO exposure. An 
E. coli MG1655 strain containing an overexpression plasmid (pSU2718-cydABX) 
was also treated with AMX after GSNO exposure. It was predicted that an 
overexpression of cytochrome bd-I would reduce the attenuation of AMX, resulting 
in a lower percentage of survival of these mutant cells than MG1655 WT. Figure 
3.6D clearly illustrates that a deletion in the cydABX operon results in the greatest 
attenuation of antibiotic efficacy, while an overexpression results in the greatest 
reduction of alleviation of bactericidal effects compared to the WT strain. 
 
These results are very significant because bacteria are exposed to NO as a result of 
host mammalian immune defences. Hagan et al. (2010) found that in E. coli isolates 
from women with urinary tract infections, cydA genes were in the top 3% of genes 
expressed, while cyoABCDE gene expression differed between patient isolates. If E. 
coli were to be increase its expression of cydA genes when presented with nitrosative 
stress during infection, bactericidal antibiotic treatment could be attenuated, creating 
a selective-pressure environment for cells which survive treatment to develop 
antibiotic resistant mutations. Further work is needed to provide further evidence that 
NO attenuates antibiotic efficacy. 
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4.3 Future Work 
The findings in this thesis could be further substantiated by repeating the 
experiments presented here with cPTIO. cPTIO forms NO2 by donating oxygen to 
NO, acting as a NO scavenger molecule (Yoshida et al. F37,2¶VUHDFWLRQZLWK
NO would keep NO from inhibiting respiration, and the antibiotic treated cells 
exposed to GSNO should have a similar survival rate to cells treated with antibiotic 
only. Experiments in this thesis could also be performed with another NO donating 
molecule in the place of GSNO. The results could be compared to that of treatment 
with GSNO, building a more robust set of results. Experiments should also be 
repeated with activated macrophages to verify if similar results are observed when E. 
coli is challenged with mammalian immune cells. 
 
In addition to these experiments, the oxygen conditions for bacterial growth could 
also be varied to create microaerobic conditions at which oxygen levels are between 
2-5% to mimic physiological oxygen levels.   This would modify the ratio of 
cytochrome expression in the electron transport chain, resulting in cytochrome bd-I 
being dominantly expressed. Since cytochrome bd-I is tolerant to NO, aerobic 
respiration would continue, but the attenuation of antibiotic killing may not be as 
pronounced and could reflect that of the ǻcyoA respiratory mutant, as respiration of 
cytochrome boඁ would be inhibited by NO. Because microaerobic conditions are 
closer to those in vivo, this set of experiments would be important in determining the 
biological importance of these findings.  However, there are other mechanisms to be 
considered in vivo, such as the presence of flavoglobin Hmp and flavorubredoxin 
NorVW detoxification systems, as well as NrfA and Hcp/Hcr reductases, all of 
which E. coli and other gram-negative bacteria use to retort the effects of NO 
(Shepherd 2016).   Therefore, additional experiments with respiratory mutants and 
later mutants for detoxification and reductases at varying oxygen conditions should 
be conducted as well to better replicate the scenario of bacterial infection in vivo. 
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